State Street’s Perspective Therapeutics CATX Stock Holding History

State Street’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.6M	Buy	6,051,771 +2,919,101	+93%	+$11M	﹤0.01%	2341
2026 Q1	$13.1M	Buy	3,132,670 +1,991,423	+174%	+$8.41M	﹤0.01%	2468
2025 Q4	$3.14M	Buy	1,141,247 +36,543	+3%	+$104K	﹤0.01%	3187
2025 Q3	$3.79M	Buy	1,104,704 +15,851	+1%	+$57.8K	﹤0.01%	3099
2025 Q2	$3.75M	Buy	1,088,853 +31,854	+3%	+$84.1K	﹤0.01%	3062
2025 Q1	$2.25M	Sell	1,056,999 -51,194	-5%	-$154K	﹤0.01%	3200
2024 Q4	$3.54M	Sell	1,108,193 -1,082,046	-49%	-$8.83M	﹤0.01%	3106
2024 Q3	$29.2M	Buy	2,190,239 +1,192,812	+120%	+$15.9M	﹤0.01%	1995
2024 Q2	$9.94M	Buy	997,427 +839,185	+530%	+$12.1M	﹤0.01%	2566
2024 Q1	$1.88M	Buy	158,242 +91,090	+136%	+$777K	﹤0.01%	3296
2023 Q4	$270K	Hold	67,152	–	–	﹤0.01%	3818
2023 Q3	$184K	Buy	67,152 +2,110	+3%	+$9.85K	﹤0.01%	3966
2023 Q2	$434K	Buy	65,042 +9,680	+17%	+$58.8K	﹤0.01%	3724
2023 Q1	$353K	Hold	55,362	–	–	﹤0.01%	3865
2022 Q4	$137K	Hold	55,362	–	–	﹤0.01%	4258
2022 Q3	$127K	Hold	55,362	–	–	﹤0.01%	4357
2022 Q2	$171K	Hold	55,362	–	–	﹤0.01%	4279
2022 Q1	$201K	Buy	55,362 +3,458	+7%	+$12.6K	﹤0.01%	4380
2021 Q4	$201K	Hold	51,904	–	–	﹤0.01%	4350
2021 Q3	$327K	Hold	51,904	–	–	﹤0.01%	4146
2021 Q2	$414K	Buy	51,904 +50,846	+4,806%	+$445K	﹤0.01%	3930
2021 Q1	$12K	Hold	1,058	–	–	﹤0.01%	3970
2020 Q4	$5K	Hold	1,058	–	–	﹤0.01%	3885
2020 Q3	$6K	Hold	1,058	–	–	﹤0.01%	3825
2020 Q2	$6K	Hold	1,058	–	–	﹤0.01%	3801
2020 Q1	$6K	Hold	1,058	–	–	﹤0.01%	3738
2019 Q4	$7K	Hold	1,058	–	–	﹤0.01%	3793
2019 Q3	$3K	Hold	1,058	–	–	﹤0.01%	3803
2019 Q2	$4K	Hold	1,058	–	–	﹤0.01%	3807
2019 Q1	$4K	Hold	1,058	–	–	﹤0.01%	3739
2018 Q4	$3K	Hold	1,058	–	–	﹤0.01%	3755
2018 Q3	$5K	Sell	1,058 -502	-32%	-$2.79K	﹤0.01%	3762
2018 Q2	$7K	Hold	1,560	–	–	﹤0.01%	3761
2018 Q1	$6K	Hold	1,560	–	–	﹤0.01%	3744
2017 Q4	$6K	Hold	1,560	–	–	﹤0.01%	3723
2017 Q3	$8K	Hold	1,560	–	–	﹤0.01%	3750
2017 Q2	$10K	Hold	1,560	–	–	﹤0.01%	3683
2017 Q1	$9K	Hold	1,560	–	–	﹤0.01%	3647
2016 Q4	$9K	Hold	1,560	–	–	﹤0.01%	3643
2016 Q3	$12K	Hold	1,560	–	–	﹤0.01%	3569
2016 Q2	$13K	Hold	1,560	–	–	﹤0.01%	3684
2016 Q1	$14K	Hold	1,560	–	–	﹤0.01%	3680
2015 Q4	$15K	Hold	1,560	–	–	﹤0.01%	3667
2015 Q3	$21K	Hold	1,560	–	–	﹤0.01%	3653
2015 Q2	$23K	Hold	1,560	–	–	﹤0.01%	3665
2015 Q1	$25K	Hold	1,560	–	–	﹤0.01%	3627
2014 Q4	$23K	Sell	1,560 -120	-7%	-$1.9K	﹤0.01%	3638
2014 Q3	$28K	Buy	1,680 +240	+17%	+$5.94K	﹤0.01%	3621
2014 Q2	$45K	Buy	+1,440	New	+$36.1K	﹤0.01%	3552

Other funds holding CATX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

State Street's CATX Position: Q2 2026 in Review

State Street increased its Perspective Therapeutics (CATX) stake by 93% in Q2 2026, buying an estimated $11M and bringing the position to 6,051,771 shares worth $20.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2341.

State Street first reported a position in CATX in Q2 2014 and has held it in 49 quarters since. The position peaked at $29.2M in Q3 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

State Street held 6,051,771 shares of Perspective Therapeutics worth $20.6M as of Q2 2026.
State Street bought 2,919,101 Perspective Therapeutics shares in Q2 2026, an estimated $11M.
Perspective Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2341 holding.
State Street first reported a position in Perspective Therapeutics in Q2 2014 and has held it in 49 quarters since.
State Street's Perspective Therapeutics position peaked at $29.2M in Q3 2024.
132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.